Refine
Year of publication
Document Type
- Article (15)
- Conference Proceeding (2)
- Preprint (2)
- Part of a Book (1)
- Working Paper (1)
Language
- English (21)
Has Fulltext
- yes (21)
Is part of the Bibliography
- no (21)
Keywords
- acute myeloid leukemia (2)
- magnetoencephalography (2)
- Advanced biliary tract cancer (1)
- Attention (1)
- BCOR (1)
- BCORL1 (1)
- BDNF (1)
- BTC (1)
- CVID (1)
- Clinical Trials and Observations (1)
- Crossmodal (1)
- Decision (1)
- EDTA-plasma (1)
- European Society for Immunodeficiencies (ESID) (1)
- Finnisch (1)
- Functional connectivity (1)
- Functional magnetic resonance imaging (1)
- German PID-NET registry (1)
- Hand-foot syndrome (1)
- Hif1α (1)
- Human behaviour (1)
- IgG substitution therapy (1)
- Independent component analysis (1)
- Multisensory (1)
- Myeloid Neoplasia (1)
- Object perception (1)
- PDGFRβ (1)
- PID prevalence (1)
- RNA PT (1)
- RNA modification (1)
- Referenzsemantik (1)
- Reflexivpronomen (1)
- Sorafenib (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- acceptable change limit (1)
- aging (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory spatial processing (1)
- beta-band activity (1)
- biosynthesis (1)
- brain-derived neurotrophic factor (1)
- c-kit (1)
- cytarabine dose (1)
- data quality (1)
- digestion artifact (1)
- drug design (1)
- dynamic causal modeling (1)
- elderly (1)
- electroencephalography (EEG) (1)
- gamma-band activity (1)
- glidobactins (1)
- inter-assay precision (1)
- loss-of-function (1)
- mass spectrometry (1)
- multicenter study (1)
- multisensory integration (1)
- nucleoside analysis (1)
- predictive coding (1)
- primary immunodeficiency (PID) (1)
- proteasome inhibitors (1)
- registry for primary immunodeficiency (1)
- risk stratification (1)
- serum (1)
- short-term memory (1)
- sound-induced flash illusion (1)
- stability (1)
- structure–activity relationships (1)
- survival (1)
- transfer entropy (1)
Institute
- Medizin (11)
- Biowissenschaften (3)
- Physik (2)
- Biochemie, Chemie und Pharmazie (1)
- Center for Financial Studies (CFS) (1)
- House of Finance (HoF) (1)
- Institut für Ökologie, Evolution und Diversität (1)
- Psychologie (1)
- Sustainable Architecture for Finance in Europe (SAFE) (1)
- Wirtschaftswissenschaften (1)
Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study.
Patients and methods: 102 unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, first 7-weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour samples were prospectively stained for sorafenib targets and potential biomarkers. Serum samples (first two cycles) were measured for vascular endothelial growth factors (VEGFs), vascular endothelial growth factor receptor 2 (VEGFR-2) and stromal cell-derived factor 1 (SDF1)α by enzyme-linked immunosorbent assay (ELISA).
Results: Gemcitabine plus sorafenib was generally well tolerated. Four and three patients achieved partial responses in the sorafenib and placebo groups, respectively. There was no difference in the primary end-point, median progression-free survival (PFS) for gemcitabine plus sorafenib versus gemcitabine plus placebo (3.0 versus 4.9 months, P = 0.859), and no difference for median overall survival (OS) (8.4 versus 11.2 months, P = 0.775). Patients with liver metastasis after resection of primary BTC survived longer with sorafenib (P = 0.019) compared to placebo. Patients who developed hand-foot syndrome (HFS) showed longer PFS and OS than patients without HFS. Two sorafenib targets, VEGFR-2 and c-kit, were not expressed in BTC samples. VEGFR-3 and Hif1α were associated with lymph node metastases and T stage. Absence of PDGFRβ expression correlated with longer PFS.
Conclusion: The addition of sorafenib to gemcitabine did not demonstrate improved efficacy in advanced BTC patients. Biomarker subgroup analysis suggested that some patients might benefit from combined treatment.